Evidence map›Paper›PMID 36048906›Full record

ArticlePloS one2022

Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F.

Yongfeng Fan, Zhengda Sun, Fraser Conrad, Weihua Wen, Lequn Zhao, Jianlong Lou, Yu Zhou, Shauna Farr-Jones, James D Marks

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yongfeng FanZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Zhengda SunZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Fraser ConradZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Weihua WenZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Lequn ZhaoZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Jianlong LouZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Yu ZhouZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
Shauna Farr-JonesZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.
James D MarksZuckerberg San Francisco General Hospital and Trauma Center, Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA, United States of America.ORCID 0000-0003-0562-3517
San Francisco General Hospital · US

Funding

Generation of therapeutic antibodies to serotype F botulismR01AI104579 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARKS, JAMES D. · 2013 to 2017
$5.4M
NIAID NIH HHS R01 AI104579
6 · The paper itself

Abstract

Generating specific monoclonal antibodies (mAbs) that neutralize multiple antigen variants is challenging. Here, we present a strategy to generate mAbs that bind seven subtypes of botulinum neurotoxin serotype F (BoNT/F) that differ from each other in amino acid sequence by up to 36%. Previously, we identified 28H4, a mouse mAb with poor cross-reactivity to BoNT/F1, F3, F4, and F6 and with no detectable binding to BoNT/F2, F5, or F7. Using multicolor labeling of the different BoNT/F subtypes and fluorescence-activated cell sorting (FACS) of yeast displayed single-chain Fv (scFv) mutant libraries, 28H4 was evolved to a humanized mAb hu6F15.4 that bound each of seven BoNT/F subtypes with high affinity (KD 5.81 pM to 659.78 pM). In contrast, using single antigen FACS sorting, affinity was increased to the subtype used for sorting but with a decrease in affinity for other subtypes. None of the mAb variants showed any binding to other BoNT serotypes or to HEK293 or CHO cell lysates by flow cytometry, thus demonstrating stringent BoNT/F specificity. Multicolor FACS-mediated antibody library screening is thus proposed as a general method to generate multi-specific antibodies to protein subtypes such as toxins or species variants.

Indexed as

Antibodies, Monoclonal, HumanizedBotulinum ToxinsFlow CytometryAnimalsAntibodies, MonoclonalCross ReactionsHEK293 CellsHumansMiceSingle-Chain AntibodiesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBotulinum Toxinsbotulinum toxin type FSingle-Chain Antibodies

Identifiers

PMID36048906
PMCPMC9436041
OpenAlexW4294045133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.